D. Boral Capital Reaffirms “Buy” Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $5.00 price target on the stock.

A number of other analysts have also recently weighed in on the stock. StockNews.com began coverage on shares of VolitionRx in a research note on Thursday. They set a “sell” rating for the company. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Price Performance

Shares of NYSE:VNRX opened at $0.55 on Thursday. The stock has a market cap of $50.97 million, a P/E ratio of -1.53 and a beta of 1.09. The firm has a fifty day moving average price of $0.60 and a 200 day moving average price of $0.64. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.02.

Institutional Trading of VolitionRx

Several hedge funds have recently made changes to their positions in the company. Lagoda Investment Management L.P. lifted its stake in shares of VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after acquiring an additional 1,481,000 shares during the period. Geode Capital Management LLC lifted its stake in shares of VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after acquiring an additional 95,900 shares during the period. Northern Trust Corp lifted its stake in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after acquiring an additional 28,579 shares during the period. Millennium Management LLC acquired a new stake in shares of VolitionRx in the 4th quarter worth $36,000. Finally, Two Sigma Securities LLC acquired a new stake in shares of VolitionRx in the 4th quarter worth $29,000. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.